A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S
A phase 3 trial of Osimertinib, Cisplatin, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT04351555 by AstraZeneca, with 358 participants enrolled, started 2020-12-16 and due to reach its primary completion in 2024-10-15. Interventions recorded: Osimertinib, Cisplatin, Carboplatin, Placebo, Pemetrexed. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan
Shares Osimertinib, Pemetrexed, Cisplatin, AstraZeneca.
- TrialSavolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Shares Osimertinib, Pemetrexed, Cisplatin, AstraZeneca.
- TrialTo Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
Shares Osimertinib, Pemetrexed, Cisplatin, AstraZeneca.
- TrialA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N
Shares Pemetrexed, Cisplatin, AstraZeneca, Carboplatin.
- TrialA Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU
Shares Osimertinib, Pemetrexed, Cisplatin, Carboplatin.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N
Shares Pemetrexed, Cisplatin, AstraZeneca, Carboplatin.
- TrialA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Shares Pemetrexed, Cisplatin, AstraZeneca, Carboplatin.
- TrialA Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.